At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Andre P. Fay, Medical Oncologist and Professor of Medicine at PUCRS School of Medicine, delivered a talk on “The Current State of Renal Oncology in Brazil”.
Dr. Fay presented striking data showing an annual incidence of around 11,000 kidney cancer cases in Brazil, with mortality exceeding 4,000, nearly 40%, almost double the rate seen in high-income countries. He attributed this to disparities in healthcare access, late-stage diagnoses, and limited availability of advanced therapies in the public health system, which serves 75% of the population.
He emphasized the gap between private and public care, with five-year survival for metastatic RCC patients reaching nearly 80% in private centers but just 42% in the public system. While novel treatments are approved in Brazil, they remain largely unavailable in public hospitals due to restrictive reimbursement policies, leaving many patients with outdated regimens. Dr. Fay called for greater access to innovative therapies, expanded clinical trial availability, and international collaboration to address these inequities.
Join us in this conversation.